{"title": "Fluarix Quadrivalent, Fluzone Quadrivalent (influenza virus vaccine quadrivalent) dosing, indications, interactions, adverse effects, and more", "author": "Journal Article", "url": "https://reference.medscape.com/drug/fluarix-quadrivalent-fluzone-quadrivalent-influenza-virus-vaccine-quadrivalent-999829", "hostname": "medscape.com", "description": "Medscape - Immunization dosing for Fluarix Quadrivalent, Fluzone Quadrivalent (influenza virus vaccine quadrivalent), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.", "sitename": "reference.medscape.com", "date": "2023-07-10", "cleaned_text": "Influenza Prophylaxis CDC's ACIP recommends that everyone aged 6 months and older receive an annual influenza vaccination 0.5 mL IM x1 dose/season For more vaccine information see http://www.cdc.gov/vaccines/ Dosing Considerations Contains the following 4 viral strains for 2023-2024 Northern Hemisphere season - A/Victoria/4897/2022 (H1N1)pdm09-like virus (new for 2023-2024) - A/Darwin/9/2021 (H3N2)-like virus (no change from last season) - B/Austria/1359417/2021 (B/Victoria lineage)-like virus (no change from last season) - B/Phuket/3073/2013-like virus (B/Yamagata lineage) (no change from last season) Dosage Forms & Strengths IM suspension - that everyone aged 6 months and older receive an annual influenza vaccinationFor more vaccine information see http://www.cdc.gov/vaccines/ Safety and efficacy years - Fluarix Quadrivalent - Not previously vaccinated: 0.5 mL IM x 2 doses - Previously vaccinated in a previous season: 0.5 mL IM x 1-2 doses Afluria or Fluzone to <36 months and not previously vaccinated: 0.25 mL or 0.5 IM x 2 doses - 6 to <36 months and previously vaccinated in a previous season: 0.5 mL IM x 1-2 doses - 36 months to <9 years and not previously vaccinated: 0.5 mL IM x 2 doses - 36 months to <9 years and previously vaccinated in a previous season: 0.5 mL IM x 1-2 doses - Flucelvax Quadrivalent - 4 to <9 years: 0.5 mL 1-2 doses 9 years - For all formulations - 0.5 mL IM x 1 dose Dosing Considerations Contains the following 4 viral strains for 2023-2024 Northern Hemisphere season - A/Victoria/4897/2022 (H1N1)pdm09-like virus (new for 2023-2024) - A/Darwin/9/2021 (H3N2)-like virus (no change from last season) - B/Austria/1359417/2021 (B/Victoria lineage)-like virus (no change from last season) - B/Phuket/3073/2013-like virus (B/Yamagata lineage) (no change from last season) Influenza Prophylaxis CDC's ACIP recommends that everyone aged 6 months and older receive an annual influenza vaccination Afluria Quadrivalent, Fluzone High-Dose Quadrivalent - Indicated for use in patients 65 years - 0.5 mL IM x1 dose/season - For more vaccine information see http://www.cdc.gov/vaccines/ Dosing Considerations Contains the following 4 viral strains for 2023-2024 Northern Hemisphere season - A/Victoria/4897/2022 (H1N1)pdm09-like virus (new for 2023-2024) - A/Darwin/9/2021 (H3N2)-like virus (no change from last season) - B/Austria/1359417/2021 (B/Victoria lineage)-like virus (no change from last season) - B/Phuket/3073/2013-like virus (B/Yamagata lineage) (no change from last season) Interactions Interaction Checker No Results Contraindicated Serious - Use Alternative Significant - Monitor Closely Minor Contraindicated (1) - ifosfamide ifosfamide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy. Serious - Use Alternative (37) - adalimumab adalimumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - alefacept alefacept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - anakinra anakinra decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - antithymocyte globulin equine antithymocyte globulin equine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - antithymocyte globulin rabbit antithymocyte globulin rabbit decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - azathioprine azathioprine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - basiliximab basiliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - budesonide budesonide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - canakinumab canakinumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - cortisone cortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - deflazacort deflazacort decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - dexamethasone dexamethasone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - elivaldogene autotemcel elivaldogene autotemcel, influenza virus vaccine quadrivalent. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. . - etanercept etanercept decreases effects influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - everolimus everolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - fludrocortisone fludrocortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - glatiramer glatiramer decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - golimumab golimumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - hydrocortisone hydrocortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - infliximab infliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - leflunomide leflunomide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - methylprednisolone methylprednisolone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - muromonab CD3 muromonab CD3 decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - mycophenolate mycophenolate decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - ocrelizumab ocrelizumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion. - ofatumumab SC ofatumumab virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible. - prednisolone prednisolone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - prednisone prednisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - rilonacept rilonacept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - secukinumab secukinumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease. - siponimod siponimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk. - sirolimus sirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - tacrolimus tacrolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - temsirolimus temsirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - teplizumab teplizumab decreases effects of influenza virus vaccine quadrivalent by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment. - tocilizumab tocilizumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - triamcinolone acetonide injectable suspension triamcinolone acetonide injectable suspension decreases virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. Monitor Closely (22) - certolizumab pegol certolizumab pegol decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. - cyclosporine cyclosporine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). . - delandistrogene moxeparvovec delandistrogene Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines. - dengue vaccine dengue vaccine, influenza virus vaccine quadrivalent. unspecified interaction mechanism. Use Caution/Monitor. Data are not available to establish safety and immunogenicity of coadministration of dengue vaccine with recommended adolescent vaccines. - ibrutinib ibrutinib decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - ifosfamide ifosfamide decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - lomustine lomustine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - mechlorethamine mechlorethamine decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - melphalan melphalan decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - mercaptopurine mercaptopurine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressants also increase risk of infection with concomitant live vaccines. - methotrexate methotrexate decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant administration of methotrexate can decrease the immunological response of vaccines. - onasemnogene abeparvovec onasemnogene abeparvovec decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. When initiating systemic corticosteriod therapy, wait 2 weeks after an inactivated vaccine. - oseltamivir oseltamivir decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated. - oxaliplatin oxaliplatin decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - ponesimod ponesimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 4 weeks before initiating ponesimod. - procarbazine procarbazine decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - rituximab rituximab, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab. - rituximab-hyaluronidase rituximab-hyaluronidase, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab. - satralizumab satralizumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. . - tralokinumab tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines. - ublituximab ublituximab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells. - voclosporin voclosporin decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment. Minor (5) - amantadine amantadine decreases effects of influenza virus vaccine quadrivalent by Other (see comment). Minor/Significance Unknown. Comment: Because of its antiviral properties, amantadine may interfere with the efficacy of live attenuated influenza vaccines (LAIV). Coadministration of LAIV and amantadine is not recommended. Inactivated influenza vaccines may be used, as appropriate. - ethotoin influenza virus vaccine quadrivalent, ethotoin. Mechanism: unknown. Minor/Significance Unknown. administration may incr levels. fosphenytoin influenza virus vaccine fosphenytoin. Minor/Significance Unknown. decr phenytoin levels. - ozanimod ozanimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Minor/Significance Unknown. No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if coadministered with ozanimod. phenytoin influenza virus vaccine quadrivalent, phenytoin. Unknown. administration may incr or decr phenytoin levels. - adalimumab Serious - Use Alternative (1)adalimumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - alefacept Serious - Use Alternative (1)alefacept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - amantadine Minor (1)amantadine decreases effects of influenza virus vaccine quadrivalent by Other (see comment). Minor/Significance Unknown. Comment: Because of its antiviral properties, amantadine may interfere with the efficacy of live attenuated influenza vaccines (LAIV). Coadministration of LAIV and amantadine is not recommended. Inactivated influenza vaccines may be used, as appropriate. - anakinra Serious - Use Alternative (1)anakinra decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - antithymocyte globulin equine Serious - Use Alternative (1)antithymocyte globulin equine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - antithymocyte globulin rabbit Serious - Use Alternative (1)antithymocyte globulin rabbit decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - azathioprine Serious - Use Alternative (1)azathioprine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - basiliximab Serious - Use Alternative (1)basiliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - budesonide Serious - Use Alternative (1)budesonide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - canakinumab Serious - Use Alternative (1)canakinumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - certolizumab pegol Monitor Closely (1)certolizumab pegol decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. - cortisone Serious - Use Alternative (1)cortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - cyclosporine Monitor Closely (1)cyclosporine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). . - deflazacort Serious - Use Alternative (1)deflazacort decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - delandistrogene moxeparvovec Monitor Closely (1)delandistrogene moxeparvovec, influenza virus vaccine quadrivalent. Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines. - dengue vaccine Monitor Closely (1)dengue vaccine, influenza virus vaccine quadrivalent. unspecified interaction mechanism. Use Caution/Monitor. Data are not available to establish safety and immunogenicity of coadministration of dengue vaccine with recommended adolescent vaccines. - dexamethasone Serious - Use Alternative (1)dexamethasone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - elivaldogene autotemcel Serious - Use Alternative (1)elivaldogene autotemcel, influenza virus vaccine quadrivalent. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. . - etanercept Serious - Use Alternative (1)etanercept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - ethotoin Minor (1)influenza virus vaccine quadrivalent, ethotoin. Mechanism: may incr or decr phenytoin levels. - everolimus Serious - Use Alternative (1)everolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - fludrocortisone Serious - Use Alternative (1)fludrocortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - fosphenytoin Minor (1)influenza virus vaccine quadrivalent, fosphenytoin. Mechanism: may incr or decr phenytoin levels. - glatiramer Serious - Use Alternative (1)glatiramer decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - golimumab Serious - Use Alternative (1)golimumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - hydrocortisone Serious - Use Alternative (1)hydrocortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - ibrutinib Monitor Closely (1)ibrutinib decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - ifosfamide Contraindicated (1)ifosfamide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy.Monitor Closely (1)ifosfamide decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - infliximab Serious - Use Alternative (1)infliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - leflunomide Serious - Use Alternative (1)leflunomide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - lomustine Monitor Closely (1)lomustine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - mechlorethamine Monitor Closely (1)mechlorethamine decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - melphalan Monitor Closely (1)melphalan decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - mercaptopurine Monitor Closely (1)mercaptopurine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressants also increase risk of infection with concomitant live vaccines. - methotrexate Monitor Closely (1)methotrexate decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant administration of methotrexate can decrease the immunological response of vaccines. - methylprednisolone Serious - Use Alternative (1)methylprednisolone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - muromonab CD3 Serious - Use Alternative (1)muromonab CD3 decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - mycophenolate Serious - Use Alternative (1)mycophenolate decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - ocrelizumab Serious - Use Alternative (1)ocrelizumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion. - ofatumumab SC Serious - Use Alternative (1)ofatumumab SC decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible. - onasemnogene abeparvovec Monitor Closely (1)onasemnogene abeparvovec decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. When initiating systemic corticosteriod therapy, wait 2 weeks after an inactivated vaccine. - oseltamivir Monitor Closely (1)oseltamivir decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated. - oxaliplatin Monitor Closely (1)oxaliplatin decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - ozanimod Minor (1)ozanimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Minor/Significance Unknown. No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if coadministered with Minor (1)influenza virus vaccine may decr phenytoin levels. - ponesimod Monitor Closely (1)ponesimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 4 weeks before initiating ponesimod. - prednisolone Serious - Use Alternative (1)prednisolone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - prednisone Serious - Use Alternative (1)prednisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - procarbazine Monitor Closely (1)procarbazine decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. . - rilonacept Serious - Use Alternative (1)rilonacept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - rituximab Monitor Closely (1)rituximab, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab. - rituximab-hyaluronidase Monitor Closely (1)rituximab-hyaluronidase, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab. - satralizumab Monitor Closely (1)satralizumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. . - secukinumab Serious - Use Alternative (1)secukinumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease. - siponimod Serious - Use Alternative (1)siponimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk. - sirolimus Serious - Use Alternative (1)sirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - tacrolimus Serious - Use Alternative (1)tacrolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - temsirolimus Serious - Use Alternative (1)temsirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - teplizumab Serious - Use Alternative (1)teplizumab decreases effects of influenza virus vaccine quadrivalent by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment. - tocilizumab Serious - Use Alternative (1)tocilizumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. - tralokinumab Monitor Closely (1)tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines. - triamcinolone acetonide injectable suspension Serious - Use Alternative (1)triamcinolone acetonide injectable suspension decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines. - ublituximab Monitor Closely (1)ublituximab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells. - voclosporin Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment. Adverse Effects >10% Afluria Quadrivalent - Pain - Myalgia Irritability (16-18%) Induration Fluarix Pain (23%) Fatigue (19.7%) - Swelling (18.5%) Muscle aches - Drowsiness (17.2%) - Irritability (15.5%) Flucelvax Quadrivalent - FluLaval Quadrivalent (59.5%) - Muscle - (8.9%) - Shivering (6.4%) - Fever (6%) - Pain, Grade 3 (1.6%) - Fatigue, Grade 3 (1.5%) - Headache, Grade 3 (1.3%) - Fever, Grade 3 (1.1%) - Redness, Grade 3 (1%) - Drowsiness, Grade 3 (1%) - Gastrointestinal Quadrivalent - Gastrointestinal symptoms (9.3%) - Shivering 3 (1.7%) - Fever (1.3%) <1% Fluarix Quadrivalent - Swelling, Grade 3 (0.8%) - Irritability, Grade 3 (0.7%) - Muscle aches, Grade 3 (0.7%) - Shivering, Grade 3 (0.5%) - Loss of appetite (0.3%) - Fever (0.3%) Flucelvax - Headache - Diarrhea (0.5-0.6%) - Arthralgia (0.3-0.5%) - Injection site pain (0.5%) - Chills (0.2-0.3%) - Nausea (0.2-0.3%) - Loss of appetite (0.2-0.3%) - Vomiting (0.2%) FluLaval Quadrivalent - Headache, Grade 3 (0.9%) - Muscle aches, Grade 3 (0.8%) - Fatigue, Grade 3 (0.8%) - Arthralgia, Grade 3 (0.8%) - Gastrointestinal symptoms, Grade 3 (0.8%) - Shivering, Grade 3 (0.6%) - Fever, Grade 3 (0.4%) Postmarketing Reports Afluria Quadrivalent Blood and lymphatic - Immune system disorders: Allergic or immediate hypersensitivity reactions, including anaphylactic shock and serum sickness - subcutaneous tissue disorders: Pruritus, urticaria, and rash - General disorders and administration site conditions: Cellulitis, large injection site swelling, influenzalike illness Fluarix Blood and lymphatic disorders: Lymphadenopathy Cardiac disorders: Tachycardia - Ear and labyrinth disorders: Vertigo - Eye disorders: Conjunctivitis, eye irritation, eye pain, eye redness, eye swelling, eyelid swelling - Gastrointestinal disorders: Abdominal pain or discomfort; swelling of the mouth, throat, and/or tongue - General disorders and administration site conditions: Asthenia, chest pain, feeling hot, injection site mass, injection site reaction, injection site warmth, body aches - Immune system disorders: Anaphylactic reaction (eg, shock), anaphylactoid reaction, hypersensitivity, serum sickness abscess, anaphylactic shock) - systems paresthesia skin reactions (eg, pruritus, urticaria, nonspecific rash) - General disorders and administration site conditions: Extensive swelling of injected limb FluLaval Quadrivalent - Blood and lymphatic disorders: pain, photophobia - Gastrointestinal disorders: Dysphagia, vomiting - General disorders and administration site conditions: Chest pain, injection site inflammation, asthenia, injection site rash, influenzalike symptoms, abnormal gait, injection site bruising, injection site sterile abscess - Immune system disorders: Allergic reactions (including anaphylaxis), connective-tissue nerve paralysis, encephalopathy, limb paralysis - Psychiatric disorders: Respiratory, thoracic, and mediastinal disorders: Dyspnea, tissue disorders: Urticaria, localized or generalized rash, pruritus, sweating Flushing, pallor Warnings Contraindications Severe hypersensitivity (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous administration of any influenza vaccine Cautions Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of vaccine Use split or purified surface antigen in children Defer vaccine with febrile illnesses until illness is resolved; may administer vaccine with minor illnesses without fever (eg, upper respiratory tract infections) Expected immune response may not be obtained in immunocompromised individuals, including those receiving immunosuppressive therapy Guillain-Barr\u00e9 syndrome has been reported within 6 weeks of receipt of influenza vaccines Tip of syringe may contain natural rubber latex Syncope reported with injectable vaccines IM injections may cause hematoma in individuals with bleeding disorders (eg, hemophilia, anticoagulant therapy) Before administration, review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions Vaccination may not protect all susceptible individuals Drug interaction overview Coadministration with other vaccines - Do not mix with any other vaccine in the same syringe or vial - There are insufficient data to assess the coadministration of influenza vaccine with other vaccines - When concomitant administration of other vaccines is required, administer at different injection sites Immunosuppressive therapies - Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to influenza vaccine Pregnancy & Lactation Pregnancy There are insufficient data on influenza vaccine in pregnant women to inform vaccine-associated risk Pregnancy exposure registry - Monitors pregnancy outcomes in women exposed to influenza vaccine during pregnancy - Healthcare providers are encouraged to register women by calling the following: Intradermal Quadrivalent or Fluzone Quadrivalent: Animal - adverse effects observed on preweaning or vaccine-related fetal malformations when administered to female rabbits before pregnancy or during pregnancy Clinical considerations - Pregnant women are at increased risk of complications associated with influenza infection compared with nonpregnant women - The CDC recommends pregnant women be immunized with influenza vaccine by injection and not the live-attenuated influenza vaccine (LAIV; intranasal influenza vaccine) - Vaccination has been shown to reduce the risk of flu-associated acute respiratory infection in pregnant women by up to 50%; immunization also confers some immunity to infants for the first several months after their birth, when they are too young to be vaccinated Lactation Unknown if distributed in human breast milk Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition Pregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Pharmacology Mechanism of Action Inactivated influenza virus types A & B subunits Conveys active immunity via stimulation of production of endogenously produced antibodies Pharmacokinetics Onset: ~2 weeks Duration: Several months Effectiveness: Varies seasonally, depending on viral strain and mutations; lower antibody response in patients aged >65 yr or immunosuppressed individuals Administration IM Administration Do not administer IV, intradermally (ID), or SC Visually inspect for particulate matter and discoloration before administration; if either condition exists, discard vaccine Fluzone High Dose Quadrivalent: Deltoid muscle of the upper arm; do not inject into the gluteal area or areas where there may be a major trunk - 12-35 months: Anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) - 36 months: Deltoid muscle - Do not inject into the gluteal area or areas where there may be a major nerve trunk ID Administration Fluzone Intradermal Quadrivalent only Preferred site of injection: Skin in the deltoid region Shake prefilled syringe Visually inspect for particulate matter and discoloration before administration Gently pierce the skin over the deltoid region; a wheal (superficial bump) and/or redness may be visible at injection site Do not aspirate Discard syringe after administration Storage at 2-8\u00baC (35-46\u00baF) - Do not freeze; discard if vaccine has been frozen - Do not use after expiration date shown on the label - Protect from light Multidose vials - Unopened vials: Refrigerate at 2-8\u00baC (35-46\u00baF) for up to 28 days Images Patient Handout Formulary Adding plans allows you to compare formulary status to other drugs in the same class. To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Adding plans allows you to: - View the formulary and any restrictions for each plan. - Manage and view all your plans together - even plans in different states. - Compare formulary status to other drugs in the same class. - Access your plan list on any device - mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. |Tier||Description| |1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.| |2||This drug is available at a middle level co-pay. Most commonly, these are \"preferred\" (on formulary) brand drugs.| |3||This drug is available at a higher level co-pay. Most commonly, these are \"non-preferred\" brand drugs.| |4||This drug is available at a higher level co-pay. Most commonly, these are \"non-preferred\" brand drugs or specialty prescription products.| |5||This drug is available at a higher level co-pay. Most commonly, these are \"non-preferred\" brand drugs or specialty prescription products.| |6||This drug is available at a higher level co-pay. Most commonly, these are \"non-preferred\" brand drugs or specialty prescription products.| |NC||NOT COVERED - Drugs that are not covered by the plan.| |Code||Definition| |PA||Prior Authorization | Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. |QL||Quantity Limits | Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. |ST||Step Therapy | Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. |OR||Other Restrictions | Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. "}